Pharmacokinetics of chlordesmethyldiazepam after single-dose oral administration in humans

  title={Pharmacokinetics of chlordesmethyldiazepam after single-dose oral administration in humans},
  author={Silvio R. Bareggi and Rodolfo Pirola and S Eva and Luigi Zecca},
  journal={European Journal of Drug Metabolism and Pharmacokinetics},
  • S. BareggiR. Pirola L. Zecca
  • Published 1 July 1986
  • Medicine, Biology
  • European Journal of Drug Metabolism and Pharmacokinetics
SummaryThe pharmacokinetics of chlordemethyldiazepam — a pharmacologically very active new 1,4-benzodiazepine derivative — in healthy subjects after administration of a single oral dose of 2 mg, was studied. Peak concentrations were reached in 1.2 ± 0.2 hours. Plasma levels declined with a biphasic pattern, and the elimination phase had a half-life of 82.9 ± 14.1 hours. The concentrations of the main metabolite of chlordemethyldiazepam, lorazepam, were about 7% of those of the parent compound… 

Quantification of chlordesmethyldiazepam by liquid chromatography-tandem mass spectrometry: application to a cloxazolam bioequivalence study.

A rapid, sensitive and specific LC-MS/MS method was developed and validated for quantifying chlordesmethyldiazepam (CDDZ or delorazepam), the active metabolite of cloxazolam, in human plasma and indicated bioequivalence since all ratios were as proposed by FDA and ANVISA.



Pharmacokinetics and Bioavailability of Intravenous, Intramuscular, and Oral Lorazepam in Humans

Six healthy volunteers received single 2- and 4-mg doses of lorazepam by 5-min intravenous infusion, in tablet form by mouth in the fasting state, and by deltoid intramuscular injection in a six-way

Plasma levels of chlorodesmethyldiazepam in humans

Chlorodesmethyldiazepam (I) concentrations were followed for 72 h in the plasma of four volunteers given 2 mg of the drug orally. The drug appears to be well absorbed, reaching peak plasma levels of

Age-related multiple-dose pharmacokinetics and anxiolytic effects of delorazepam (chlordesmethyldiazepam).

Data indicate that CDDZ is more slowly eliminated and less metabolized as age increases, and older patients improved significantly less than those of group 1 and had also an higher incidence of side-effects.

Analysis of lorazepam and its glucuronide metabolite by electron-capture gas--liquid chromatography. Use in pharmacokinetic studies of lorazepam.

This paper describes a rapid and sensitive method for analysis of lorazepam and its glucuronide metabolite in plasma and urine following therapeutic doses of lOrazepAm in humans, and the applicability of the method to pharmacokinetic studies of l orazepAM is demonstrated.

Novel application of proton nuclear magnetic resonance spectroscopy in the identification of 2'-chloronordiazepam metabolites in the dog.

A novel method is introduced to identify the 4'-hydroxy isomer 3, based on attributing different sets of NMR substituent effect parameters to hydroxyl groups, depending on whether these groups are meta or para to the benzodiazepinimine function.

NL-FIT: a microcomputer program for non-linear fitting.

Gas chromatographic determination of chlorodesmethyldiazepam and lorazepam in rats and mice.

Structure-activity relationships within the class of 1,4-benzodiazepines: presence of chlorine and central nervous system activities.